Search for: "Lilly v. State"
Results 741 - 760
of 915
Sorted by Relevance
|
Sort by Date
10 Mar 2015, 11:55 pm
As in Hammon v. [read post]
8 May 2013, 6:23 am
The case was AT&T Mobility LLC v. [read post]
31 Jul 2018, 7:58 am
The ruling of the CJEU brings to mind the test proposed by Warren J. in Eli Lilly v Human Genom Sciences [2014] EWHC 2404 (Pat) (18 July 2014)). [read post]
30 Apr 2011, 5:22 am
” Eli Lilly & Co. v. [read post]
25 Sep 2017, 7:22 pm
Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed. [read post]
25 Sep 2017, 7:22 pm
Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed. [read post]
24 Jul 2012, 1:24 pm
Ltd v. [read post]
2 Nov 2011, 4:53 am
The Kat had this brilliant idea for what you get when you cross 'Neutrokine-a' with 'genome' Hot off the press and not yet digested, this morning's ruling of the United Kingdom's Supreme Court in Human Genome Sciences Inc. v Eli Lilly and Company [2011] UKSC 51, will be the subject of considerable analysis in the coming days and weeks. [read post]
5 Mar 2024, 10:55 am
In U.S. ex rel Adventist Health Sys., et al. v. [read post]
25 Jul 2011, 1:07 am
will be decided this week, this time by the European Patent Office in Human Genome Sciences Inc v Eli Lilly and Company [2010] EWCA Civ 33. [read post]
13 Feb 2009, 5:54 am
Rivers v. [read post]
13 Feb 2009, 5:54 am
Rivers v. [read post]
13 Feb 2009, 5:54 am
Rivers v. [read post]
3 Apr 2008, 7:27 am
Eli Lilly & Co., ___ F. [read post]
30 Nov 2007, 8:00 am
Law, for the proposition that US territoriality is becoming increasingly uncoupled from sovereignty and geography.Vested Interests and Territorial Claims Burden Patent Law ReformVested interests and territorial claims are the main impediments to patent reform in the United States. [read post]
30 Apr 2019, 5:29 am
This focused on the three-step test of the Eli Lilly v Actavis UK Supreme Court decision and the subsequent UK cases applying that test. [read post]
27 Dec 2013, 8:44 am
Eli Lilly & Co., No. 0:13-591-CMC, 2013 U.S. [read post]
24 Jan 2015, 8:19 pm
The answer is not clear-cut but as a general rule the post-filing data can only be ‘confirmatory’ of disclosure in the specification.As an aside, it is worth mentioning Human Genome Sciences v Eli Lilly where the main issue was how much data is required in the specification to support therapeutic use of an antibody to a new protein (see Katpost here).Why is it important to claim broadly in biotech? [read post]
11 Jan 2012, 2:02 pm
Eli Lilly & Co., 119 F.3d 1559, 1566 (Fed. [read post]
17 Apr 2008, 10:39 am
Eli Lilly & Co., 536 F. [read post]
